Wednesday, January 27, 2010


Arrayit's microarray technology empowers the arrangement of a miniaturized array of test sites or "spots" on a planar surface. Each spot is typically around 100 micrometers in diameter , but they can be larger and smaller as well. With our platform the microarrays can contain a wide variety of biological molecules, but most often they are some form of DNA or protein and the planar surface is most often a specially prepared glass slide. The biomolecules on the slide act as targets for a test sample applied in solution to the microarray. Arrayit's microarray format allows many tests or experiments to be performed simultaneously, miniaturized and in parallel, leading to the generation of huge amounts of biological information for the application of only a tiny amount of test sample.Microarrays can be put into a larger catagory called "biochips" with microarrays being the main technology component of a microfluidic testing device.The purpose of this blog entry is to review how Arrayit's technology fits into the overall market aimed at analysis of proteins and DNA.

Current applications include:
1) expression profiling;
2) genotyping
3) cytogenetics
4) serum-based diagnostics;
5) protein-protein binding assays;
6) dna-dna binding assays;
7) drug-target binding
8) receptor epitope binding
9) small molecule HTS

Arrayit has a uniqueset of products in both DNA and protein array testing equipment and supplies using screening reagents and instruments for analysis of individual components of cells, body fluids, blood, serum or plasma. Arrayit has sales worldwide with tremendous growth potential in the area of diagnostics. Arrayit products are used in research labs, hospital labs, and commercial laboratories.

The main technology driver of the Arrayit platform is our ex-situ microarray manufacturing technology. This is the cornerstone of our platform that is able to make more microarrays with less sample, faster than any other technology in the world.

- How can Arrayit's microarray tools and technologies facilitate drug discovery, design and development?

Answer: By providing specific functional information about genes and proteins drug designers can have reliable and measurable targets for their therapeutics with the ability to measure efficacy.

- What are the main types of microarray technologies that are currently available?

Answer: The most reliable and versatile type of microarray is made with Arrayit's ex-situ technology. The reason for this is only through an ex-situ technique can the biomolecules being used to manufacture the microarray be checked for quality prior to the microarray manufacturing step. In-situ manufactured microarrays can only be checked for quality after the in-situ manufacturing step and in-situ microarrays are limited to synthetic biomolecules only.

- Who are the current key players in this marketplace?

Answer: Arrayit has been a key player in the research market for more than a decade. Arrayit's platform is now slated to be used in clinical diagnostic applications.

- Which microarray market areas have the greatest potential for growth?

Answer: Diagnostics

- What is the current state of the microarray market?

Answer: Use of protein and peptide microarrays is increasing. Many end users have become more sophisticated, with a significant trend in outsourcing. Most doctors and scientists simply want accurate data, fast and at a good price. ...they don't care how the correct answer is generated.

- Which biotechnology and pharmaceutical companies are investing in microarraysolutions?

Answer: All major research institutions, biotech and pharmaceutical companies use microarray technology.

- What are the main microarray business strategies adopted by leading companies?

Answer: Depends on what assay is being targeted. Unlike other microarray companies, Arrayit's platform is extremely flexible in the types of applications that can be done. This leads to a broad marketing strategy and opens up more opportunties in diagnositcs.

- What are the benefits of Arrayit's microarray technology platform?

Answer: The ability to quantitively measure any type of biomarker including, mRNA, DNA, Protein, Peptide, and Carboydrate in a microarray format.